News :: Kazia Therapeutics (KZIA)

Mar 21, 2024 8:52 am EDT Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 13, 2024 8:00 am EDT Kazia announces presentation of new data at AACR Annual Meeting

Feb 21, 2024 7:30 am EST Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Jan 18, 2024 7:30 am EST KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Dec 5, 2023 6:02 pm EST Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 1, 2023 8:00 am EST Kazia Therapeutics Announces $2 Million Registered Direct Offering

Nov 29, 2023 7:01 am EST KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Nov 21, 2023 7:30 am EST KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 20, 2023 4:30 pm EST KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION